Tobam Vertex Pharmaceuticals Inc Transaction History

Tobam

$548 Million
Q3 2024

A detailed history of Tobam transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Tobam holds 481 shares of VRTX stock, worth $216,916. This represents 0.04% of its overall portfolio holdings.

Number of Shares

481

Previous 625 23.04%

Holding current value

$216,916

Previous $293,000 23.55%

% of portfolio

0.04%

Previous 0.05%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 09, 2024	SELL	$460.0 - $505.78 $66,240 - $72,832	-144 Reduced 23.04%	481 $224,000
Q2 2024 Jul 29, 2024	SELL	$392.81 - $485.53 $533,435 - $659,349	-1,358 Reduced 68.48%	625 $293,000
Q1 2024 May 02, 2024	SELL	$407.69 - $446.08 $35,876 - $39,255	-88 Reduced 4.25%	1,983 $829,000
Q4 2023 Jan 26, 2024	SELL	$343.0 - $410.68 $283,318 - $339,221	-826 Reduced 28.51%	2,071 $843,000
Q3 2023 Oct 31, 2023	SELL	$338.18 - $362.46 $109,570 - $117,437	-324 Reduced 10.06%	2,897 $1.01 Million
Q4 2022 Feb 02, 2023	SELL	$285.76 - $321.48 $39,434 - $44,364	-138 Reduced 4.11%	3,221 $930,000
Q3 2022 Nov 02, 2022	SELL	$273.83 - $305.53 $3.75 Million - $4.19 Million	-13,701 Reduced 80.31%	3,359 $973,000
Q2 2022 Aug 02, 2022	SELL	$234.96 - $292.55 $3.78 Million - $4.7 Million	-16,067 Reduced 48.5%	17,060 $4.81 Million
Q1 2022 Apr 25, 2022	BUY	$221.42 - $260.97 $6 Million - $7.08 Million	27,114 Added 450.92%	33,127 $8.65 Million
Q4 2021 Feb 15, 2022	BUY	$177.01 - $223.45 $67,440 - $85,134	381 Added 6.76%	6,013 $1.32 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $859,607 - $961,969	4,739 Added 530.68%	5,632 $1.02 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $228,295 - $270,668	893 New	893 $243,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

News

Stay updated on Tobam with notifications on news.

Account